Table 2 Comparison of HCCs showing a complete response according to mRECIST with complete and incomplete lipiodol retention
Incomplete (N = 16) | Complete (N = 30) | p value+ | |
|---|---|---|---|
Serum AFP level (μg /L) ± SD | 44 ± 110 | 93 ± 279 | 0.50 |
HCC Size (mm) ± SD | 22.9 ± 0.8 | 22.8 ± 10 | 0.96 |
HCC location | 1.00 | ||
- Left lobe | 5 (32%) | 10 (33%) | |
- Right lobe | 11 (68%) | 20 (66%) | |
Capsule appearance | 4 (25%) | 9 (30%) | 0.50 |
Selective cTACE Treatment | 10 (62%) | 23 (76%) | 0.24 |
Mean Delivered Dose (mg) ± SD | 22 ± 11 | 26 ± 13 | 0.54 |
Embolic agent | |||
- Gelfoam | 14 (87%) | 26 (86%) | 0.22 |
- PVA particles | 0 (0%) | 3 (10%) | |
- None | 2 (13%) | 1 (4%) | |
CBCT guidance | 9 (56%) | 17 (56%) | 0.61 |
Local progression* | 15 (94%) | 10 (30%) | <0.01 |
Mean delay of local progression (months) ± SD | 11.1 ± 2 | 13.4 ± 3 | 0.51 |